- Non-Invasive differentiation of IBS from IBD (Qualitative)
- Assists physicians in monitoring intestinal inflammation in Crohn’s Disease and Ulcerative Colitis (Quantitative)
- 90% specific for identifying inflammation in patients with active Inflammatory Bowel Disease
- Highly specific in ruling out Irritable Bowel Syndrome
- Reduces the need for invasive procedures
- Higher level of patient acceptance than endoscopy
An estimated 30 million Americans suffer from Irritable Bowel Syndrome (IBS), a disorder characterized by crampy abdominal pain, bloating, constipation, and/or diarrhea. The same clinical picture may be seen in individuals with Ulcerative Colitis (UC) and Crohn’s Disease (CD). Collectively known as Inflammatory Bowel Disease (IBD), UC and CD affect more than 1 million Americans. Although individuals with IBS may experience severe discomfort and require symptomatic treatment, patients with IBD may develop rectal bleeding and permanent intestinal damage. Furthermore, patients with IBD frequently require long-term steroid therapy and immunosuppressive agents. Consequently, distinguishing IBS from IBD is critical for patient management.
In patients with active IBD, lactoferrin, a proven marker of inflammation, is released from leukocytes infiltrating the intestinal mucosa. Whereas fecal lactoferrin tends to be elevated in patients with active IBD, lactoferrin is 86% sensitive and 100% specific in distinguishing IBD from IBS, thus making fecal lactoferrin an important diagnostic tool (Am J Gastroenterol. 2003;98:1309-1394).
1 gram frozen random stool sample in a plastic screw-cap container (0.3 gram minimum).
*The CPT Codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.